U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry UNKNOWN
Molecular Formula C13H14N2O.C4H4O4
Molecular Weight 330.3352
Optical Activity ( + )
Defined Stereocenters 0 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of VELNACRINE MALEATE, (+)-

SMILES

OC(=O)\C=C/C(O)=O.NC1=C2C=CC=CC2=NC3=C1C(O)CCC3

InChI

InChIKey=NEEKVKZFYBQFGT-BTJKTKAUSA-N
InChI=1S/C13H14N2O.C4H4O4/c14-13-8-4-1-2-5-9(8)15-10-6-3-7-11(16)12(10)13;5-3(6)1-2-4(7)8/h1-2,4-5,11,16H,3,6-7H2,(H2,14,15);1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula C13H14N2O
Molecular Weight 214.2631
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Velnacrine (9-amino-1,2,3,4-tetrahydroacridin-1-ol) is an inhibitor of acetylcholinesterase. It was studied for the treatment of Alzheimer's disease however development was discontinued. There has been no research into the use of velnacrine as a cognitive enhancer in the treatment of Alzheimer's disease since 1994. The FDA peripheral and CNS drug advisory board voted unanimously against recommending approval. This review shows the toxic nature of velnacrine, and provides no evidence of efficacy.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.79 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Velnacrine for Alzheimer's disease.
2004
Patents

Patents

Sample Use Guides

Velnacrine for the treatment of Alzheimer's disease (a double-blind, placebo-controlled trials): 10, 25, 50 and 75 mg t.i.d. The 225 mg/day dose appears to be safe for use in multicenter outpatient trials of velnacrine efficacy in Alzheimer's disease.
Route of Administration: Oral
Human erythrocyte suspensions were incubated with acetylcholine and choline in the absence or presence of 10 microM atropine or 10 microM velnacrine maleate.
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:17:47 GMT 2023
Edited
by admin
on Sat Dec 16 10:17:47 GMT 2023
Record UNII
WR9885GALS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VELNACRINE MALEATE, (+)-
Common Name English
1-ACRIDINOL, 9-AMINO-1,2,3,4-TETRAHYDRO-, (+)-, (Z)-2-BUTENEDIOATE (1:1) (SALT)
Systematic Name English
1-ACRIDINOL, 9-AMINO-1,2,3,4-TETRAHYDRO-, (+)-, (2Z)-2-BUTENEDIOATE (1:1) (SALT)
Systematic Name English
Code System Code Type Description
CAS
121445-25-8
Created by admin on Sat Dec 16 10:17:47 GMT 2023 , Edited by admin on Sat Dec 16 10:17:47 GMT 2023
PRIMARY
FDA UNII
WR9885GALS
Created by admin on Sat Dec 16 10:17:47 GMT 2023 , Edited by admin on Sat Dec 16 10:17:47 GMT 2023
PRIMARY
PUBCHEM
5702293
Created by admin on Sat Dec 16 10:17:47 GMT 2023 , Edited by admin on Sat Dec 16 10:17:47 GMT 2023
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER